Proportionate evidence in biosimilar development: when a comparative efficacy study can still change the regulatory...

Biosimilar regulation was established using a systematic, stepwise framework in which clinical comparisons addressed residual uncertainties following comprehensive quality and pharmacokinetic assessments. Advances in analytical resolution, clinical pharmacology, and over two decades of regulatory expertise have substantially mitigated this residual uncertainty. This publication examines circumstances in which a comparative efficacy study could still influence regulatory decisions. It presents four original analyses: a quantitative comparison of the nominal resolution of selected analytical methodologies, combined with predefined equivalence criteria, within specific clinical programs that operate at disparate scales and are used solely to demonstrate respective resolution and acceptance thresholds. Additionally, an audit of publicly available regulatory outcomes identifies 100 United States 351(k)-licensed biosimilar and interchangeable products, alongside 149 authorized European biosimilars. It also classifies 16 European nonpositive initial outcomes: nine primarily driven by quality, manufacturing, or product bridging issues; two involving clinical pharmacology or overall comparability; one following a positive opinion; and four lacking sufficient public detail. Notably, no case identified a failed comparative efficacy study as the sole decisive factor, a conclusion limited by excluding programs abandoned before filing from the dataset. An analysis of participant burden estimates indicates an aggregate of more than 10,000 enrollments for programs approved through 2019. A Bayesian value of information model shows that, under a defined base case, the net benefit of such a study diminishes once prior evidence indicates that clinical similarity substantially exceeds the decision threshold. The framework continues to emphasize targeted clinical evidence relevant to unresolved mechanisms, uncharacterized local exposure, potential immune risks, or unaddressed population-specific questions.